Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

6 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

Medical Cannabis, watch list of pot-related stocks
nipper
post Posted: Mar 4 2020, 01:35 AM
  Quote Post


Posts: 6,784
Thanks: 2337


The medicinal cannabis industry has suffered a significant setback, with stock values plummeting as the product takes longer than expected to get to market.
QUOTE
Key points:
  • The industry is experiencing a correction, with people who sought a quick profit from the pot boom now feeling the pinch
  • Some companies have lost 50 to 80 per cent of their stockmarket value in the past year
  • Insiders say the industry's major bottleneck is being able to turn an illegal recreational substance into a pharmaceutical-grade drug


.https://www.abc.net.au/news/2020-03-03/medicinal-cannabis-shares-takes-hit-as-market-reality-sets-in/12012010?section=business



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 14 2020, 11:36 AM
  Quote Post


Posts: 6,784
Thanks: 2337


And another one, likely IPO in Feb
Little Green Pharma Ltd

some waffle at: https://smallcaps.com.au/little-green-pharm...nnabis-exports/



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 6 2020, 10:44 AM
  Quote Post


Posts: 6,784
Thanks: 2337


Here's an allied stock. Due to list Jan 2020
QUOTE
Emerald Clinics Limited EMD is an Australian incorporated company that operates a network of specialist medical clinics and uses purpose-built software and technology to gather high quality clinical data from informed and consenting patients.

Emerald is a clinical services and healthcare technology company focussed on the provision of care for patients clinically determined to have exhausted conventional therapies and who may be suitable for cannabinoid-based medicines. In addition, Emerald uses technology to capture clinical data that can be used to generate clinical evidence relating to the safety and efficacy of cannabinoid-based medicines.

Emerald has established four medical centres in Australia including one site each in West Leederville WA, Woolloomooloo NSW, Tintenbar NSW and Richmond VIC. Additional Clinics are planned across Australia within the next 12 months. Emerald is also considering the viability of expanding its operations to the United Kingdom
- could be an interesting niche player with growth prospects (and hopefully high margins)




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Dec 26 2019, 07:22 AM
  Quote Post


Posts: 6,784
Thanks: 2337


QUOTE
Industrial hemp and medicinal cannabis business Elixinol Global is now down 90 per since April 2019 when shares hit $5.93 on a valuation around $740 million.

The stock changed hands for just 51¢ this morning as problems mount up globally for the company. In the US it's facing a potential class action lawsuit alleging that it mislabelled its products as dietary supplements, while it also admitted Elixinol Japan had sold non-compliant hemp-derived products.

For the nine months to September 30, it posted an operating cash loss of $11.4 million on sales of $40.7 million, with $34.3 million in cash on hand. The former market darling is forecasting estimated cash outflows (before sales) of $24.2 million over the quarter to 31 Dec.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Dec 21 2019, 06:43 AM
  Quote Post


Posts: 6,784
Thanks: 2337


The Psychedelic Renaissance

... a fair synopsis (although a bit foggy), and wishful thinking by someone

https://www.sharecafe.com.au/2019/12/20/a-p...ic-renaissance/

but as for this!!
QUOTE
Many microdosers come from the San Francisco area with the typical profile being an “übersmart twentysomething” curious to see whether microdosing will help him or her work through technical problems and become more innovative




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Nov 25 2019, 07:44 PM
  Quote Post


Posts: 6,784
Thanks: 2337


QUOTE
Cann Group Ltd (ASX: CAN): The cannabis company’s shares are currently the worst performers on the All Ordinaries on Monday afternoon. At one stage they were down by 33% to 49 cents. They have since narrowed this decline slightly, but are still down 27% to 53.5 cents at the time of writing.
Why is the Cann Group share price crashing lower?
Investors appear to be selling Cann Group’s shares today after looking over the production plans it announced last week. Previously, the company was planning to complete the Mildura facility in a single stage development. This would give it a total capacity of 70,000 kgs of cannabis flower at an estimated project cost of $184 million. This was expected to generate annual revenues of approximately $220 million to $280 million

However, in response to weaker than expected demand and an oversupply of cannabis, management intends to split its construction into three stages. It estimates that first stage production will be around 25,000 kgs. And while management hasn’t updated its revenue forecast yet, I suspect the market is anticipating a sharp downgrade. Especially given the abundance of cannabis flower and the limited use that its offtake partner, Aurora Cannabis, has for it at present.
....
It isn’t all doom and gloom in the cannabis industry on Monday. Both AusCann Group Holdings Ltd (ASX: AC8) and Botanix Pharmaceuticals Ltd (ASX: BOT) are up 4.5% following updates this morning.

The AusCann share price is up after appointing TGA-licensed Aspen Pharmacare Australia to provide packaging for its medicinal cannabis pharmaceutical products.

Whereas the Botanix share price is up after following a US DEA announcement. It advised Botanix’s partner Purisys, that its synthetic cannabidiol product is no longer scheduled as a controlled substance. Botanix Executive Chairman, Vince Ippolito, believes this change will make a major difference to the speed of developing its products and greatly reduces the risks and costs of clinical development..

Motley Fool



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 

Featured Stock Stories





Nopoo
post Posted: Jan 29 2019, 01:55 PM
  Quote Post


Posts: 133
Thanks: 4


In Reply To: Nopoo's post @ Jan 9 2019, 04:08 AM


$BBT.C Benchmark Botanics Appoints Agriculture Expert



#cannabis #stocks #marijuana #investing #MJ #microcaps

https://web.tmxmoney.com/article.php?newsid..._symbol=BBT:CNX




--------------------
Nopoo
 
Nopoo
post Posted: Jan 9 2019, 04:08 AM
  Quote Post


Posts: 133
Thanks: 4



$BBT.C Benchmark Botanics is a diversified multi-licensed cannabis producer focused on its three-way vertical business model, with sales and distribution into the medical, pharmaceutical, and recreational markets in Canada, and the EU. The Company’s business plan includes a strategy to become the first Canadian licensed producer to enter and sell nutraceutical medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics’ 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion of an additional 50,000 square foot facility. Along with cultivation and production, the company’s Peachland BC facility also provides propagation, cultivation, cloning, storage, research & development, genetics, CBD oil extraction and is progressing towards an EU-GMP certification.

As part of its expansion strategy the company’s plans to build up to 236,940 sq. ft. of growing space to produce 25,550 kg of cannabis per year and is building its second facility a 100% owned 4-acre (1,618 ha) Pitt Meadows Greenhouse Operations, in BC.

The Company has established several European Union partnerships including the rights to “The Bulldog” trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world.

Benchmark Botanics has entered into an agreement with Barcelona, Spain-based Green BCN Corp. (“BBG Projects”) for the development and production of new strains of cannabis plant varieties and their propagating material for sale and distribution. Benchmark Botanics has also established German commercial partnerships to import the Company’s products into Germany and distribute throughout Europe.

www.benchmarkbotanics.com




--------------------
Nopoo
 
blacksheep
post Posted: Dec 8 2018, 01:50 PM
  Quote Post


Posts: 6,791
Thanks: 2305


In Reply To: blacksheep's post @ Dec 7 2018, 02:41 PM

Extract from this US article https://mjbizdaily.com/aphria-cannabis-stock-plunging/. A number of ASX listed cannabis stocks have entered into arrangements with Canadian companies. Begs the question - how much due diligence have those ASX listed companies done on their partners?

QUOTE
2. Bigger than Aphria

The accusations could have broader implications for the industry and call into question just how much due diligence occurs as cannabis companies embark on their rapid expansions, said Andrew Kessner, an analyst with New York-based investment advising firm William O’Neil.

“Things have been moving so quickly in this space that a lot of companies have gotten a pass as far as what they’ve been spending their money on and why,” he said. “I think investors are starting to wise up and ask, ‘What’s really under the hood?’

“Are these executives really being good stewards of investor capital or are they inflating their company’s position to bring up valuations and do another round of funding?”

Damas agreed.

“It’s this sort of thing that could be the crack in the dike – so to speak,” he said. “It’s going to have ramifications for the whole industry.

“Other people are going to start taking a look at those assets that are far and away and wonder if they’re really worth what management is paying.”

3. Reassessing international plays

Aphria’s stock selloff could also signal just how critically investors view the international footprints of Canada’s larger cannabis producers, Kessner said.

“These companies have used the Canadian (capital) markets as a launching pad to raise money based on their plans to grow internationally,” he said.

“If that growth story – of being a global player – gets shot down, then their valuation begins to make no sense.”

Analysts at both GMP Securities and Bank of Nova Scotia moved their ratings for Aphria to “under review” after the short-seller report.

“We believe that management’s credibility may have been impacted by the allegations raised in this report,” GMP analysts wrote in a note to investors. “It is unclear at this point how the company will re-establish trust with investors.”


Might be a bit out of date, but - The Cannabis Index: A complete guide to cannabis stocks on the ASX - https://www.businessnewsaus.com.au/articles...on-the-asx.html




--------------------
The herd instinct among forecasters makes sheep look like independent thinkers. Edgar Fiedler

If the freedom of speech is taken away then dumb and silent we may be led, like sheep to the slaughter. George Washington
 
blacksheep
post Posted: Dec 7 2018, 02:41 PM
  Quote Post


Posts: 6,791
Thanks: 2305


In Reply To: blacksheep's post @ Oct 16 2018, 09:30 AM

No doubt relevant to ASX listed pot stocks also. See the Short Selling thread for more on Aphira, including Hindenburgs report
Cracks Form in Cannabis Surge After Short Seller Targets Aphria
QUOTE
Pot-stock euphoria appears to be wearing off, with a short-seller report targeting Aphria Inc. raising broader questions about governance and financial disclosure in the adolescent industry.

Aphria’s stock price was chopped in half and several other pot stocks including Aurora Cannabis Inc. and Canopy Growth Corp. fell following the report from Quintessential Capital Management and Hindenburg Research, which alleged Aphria paid inflated prices for assets held by insiders.

The report is adding to concerns that the sector can’t justify the lofty valuations reached shortly before Canada legalized recreational cannabis in October. Since Oct. 16, the day before legalization took effect, the Horizons Marijuana Life Sciences Index ETF has lost 41 percent, pressured by supply shortages and weaker-than-expected earnings.


QUOTE
“This is like any industry, you’ve got to look at management teams, you’ve got to look at governance,” Engel said in an interview at Bloomberg’s Toronto office. “We’ve got a number of companies in this space where the CEO is the chair. From a governance perspective that’s not ideal, you need independence.”

Many pot companies are criticized for their frequent use of press releases in what appears to be a blatant attempt to boost their stocks, said John O’Connell, CEO of Toronto-based investment manager Davis Rea Ltd., which has been short Aphria’s stock since September.

“The rubber’s going to start hitting the road here pretty quickly in terms of who actually has executed on their business plan and not just promoted the stock,” O’Connell said.


QUOTE
Looking ahead to 2019, it appears that the correlation between pot stocks will continue to break down as some companies successfully mature and others fail, said Rosen.

“There’s a small group of companies that will survive and a large number that are going to collapse.”


read more - https://www.bloomberg.com/news/articles/201...-targets-aphria



--------------------
The herd instinct among forecasters makes sheep look like independent thinkers. Edgar Fiedler

If the freedom of speech is taken away then dumb and silent we may be led, like sheep to the slaughter. George Washington
 
 


6 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING